A number of other equities research analysts have also recently commented on OPK. Jefferies Group reissued a hold rating and issued a $10.00 price objective (down previously from $11.00) on shares of Opko Health in a research note on Friday, June 17th. Zacks Investment Research lowered Opko Health from a hold rating to a sell rating in a report on Friday, July 1st. Standpoint Research raised their target price on Opko Health from $16.00 to $18.00 and gave the company a buy rating in a report on Tuesday, June 21st. Deutsche Bank AG dropped their target price on Opko Health from $11.00 to $10.00 and set a hold rating on the stock in a report on Thursday, June 16th. Finally, JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the company a buy rating in a report on Tuesday, August 9th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Opko Health has a consensus rating of Buy and a consensus target price of $13.20.
Shares of Opko Health (NYSE:OPK) traded down 3.42% on Monday, reaching $9.61. The company’s stock had a trading volume of 1,645,019 shares. The stock has a market cap of $5.29 billion and a P/E ratio of 40.21. The firm’s 50 day moving average is $10.06 and its 200-day moving average is $10.09. Opko Health has a 52-week low of $7.12 and a 52-week high of $11.85.
Opko Health (NYSE:OPK) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.02 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. During the same period last year, the business posted ($0.09) EPS. The company’s revenue was up 742.2% on a year-over-year basis. On average, equities research analysts forecast that Opko Health will post ($0.05) EPS for the current year.
In other news, CEO Phillip Md Et Al Frost bought 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was acquired at an average cost of $9.91 per share, with a total value of $99,100.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $30,413,304.41. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new position in shares of Opko Health during the second quarter valued at $100,000. Financial Architects Inc boosted its position in shares of Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock valued at $102,000 after buying an additional 1,940 shares during the period. First Citizens Bank & Trust Co. bought a new position in shares of Opko Health during the second quarter valued at $103,000. Williams Jones & Associates LLC boosted its position in shares of Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock valued at $106,000 after buying an additional 8,800 shares during the period. Finally, Nuveen Fund Advisors LLC bought a new position in shares of Opko Health during the second quarter valued at $131,000.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.